Knowledge deficits related to the QT interval could affect patient safety

被引:31
作者
LaPointe, NMA
Al-Khatib, SM
Kramer, JM
Califf, RM
机构
[1] Duke Univ, Ctr Med, Duke Clin Res Inst, CERT, Durham, NC 27715 USA
[2] Duke Univ, Ctr Med, Div Cardiol, Dept Med, Durham, NC 27715 USA
关键词
QT interval; electrocardiograph; surveys; safety;
D O I
10.1046/j.1542-474X.2003.08211.x
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Background: Recently, some QT-prolonging, noncardiac medications were withdrawn from the U.S. drug market because of continued inappropriate use by health care practitioners despite warnings and label changes from both the drug manufacturers and the U.S. Food and Drug Administration. This led us to assess the health care practitioners' knowledge of the QT interval and medications that may prolong it. Methods: We surveyed health care practitioners, primarily specialists in cardiology, to identify knowledge deficits related to the QT interval. Results: From a total of 334 survey respondents, 157 (47%) were physicians; 271 (81%) stated that cardiology was their area of specialization. Most of the respondents (86%) said that they would check an ECG before and after starting QT-prolonging medications, but less than half (42%) of all respondents and only 60% of physician respondents were able to accurately measure a sample QT interval on the survey. Less than two-thirds (63%) of respondents were able to accurately identify possible QT-prolonging medications, while only about half (51%) could accurately identify medication combinations that might prolong the QT interval. Conclusions: We identified significant knowledge deficits regarding the QT interval and QT-prolonging medications. Additional research is needed to determine the extent to which these knowledge deficits may negatively affect patient safety. We must also develop effective strategies to eliminate these deficits.
引用
收藏
页码:157 / 160
页数:4
相关论文
共 11 条
[1]
Cavuto NJ, 1996, JAMA-J AM MED ASSOC, V275, P1086, DOI 10.1001/jama.275.14.1086
[2]
The safety of newly approved medicines - Do recent market removals mean there is a problem? [J].
Friedman, MA ;
Woodcock, J ;
Lumpkin, MM ;
Shuren, JE ;
Hass, AE ;
Thompson, LJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (18) :1728-1734
[3]
Rates of Torsades de Pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin [J].
Frothingham, R .
PHARMACOTHERAPY, 2001, 21 (12) :1468-1472
[4]
GIARDINA EGV, 1979, CIRCULATION, V60, P1045, DOI 10.1161/01.CIR.60.5.1045
[5]
QT prolongation and Torsades de pointes associated with clarithromycin [J].
Lee, KL ;
Jim, MH ;
Tang, SC ;
Tai, YT .
AMERICAN JOURNAL OF MEDICINE, 1998, 104 (04) :395-396
[7]
QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients [J].
Reilly, JG ;
Ayis, SA ;
Ferrier, IN ;
Jones, SJ ;
Thomas, SHL .
LANCET, 2000, 355 (9209) :1048-1052
[8]
QT INTERVAL PROLONGATION PREDICTS CARDIOVASCULAR MORTALITY IN AN APPARENTLY HEALTHY POPULATION [J].
SCHOUTEN, EG ;
DEKKER, JM ;
MEPPELINK, P ;
KOK, FJ ;
VANDENBROUCKE, JP ;
POOL, J .
CIRCULATION, 1991, 84 (04) :1516-1523
[9]
Contraindicated use of cisapride - Impact of food and drug administration regulatory action [J].
Smalley, W ;
Shatin, D ;
Wysowski, DK ;
Gurwitz, J ;
Andrade, SE ;
Goodman, M ;
Chan, KA ;
Platt, R ;
Schech, SD ;
Ray, WA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (23) :3036-3039
[10]
TORSADES-DE-POINTES ASSOCIATED WITH DRUGS AND TOXINS - RECOGNITION AND MANAGEMENT [J].
STRATMANN, HG ;
KENNEDY, HL .
AMERICAN HEART JOURNAL, 1987, 113 (06) :1470-1482